ArticleScience translational medicine2019
Targetable genetic alterations of
Abstract read
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 64 citations in OpenAlex.
- A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.Blood cancer discovery · 2026Article
- Article
- The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities.Blood cancer discovery · 2026Review
- Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.Genome biology · 2026Article
- In Silico Perturbation Identifies Transcription Factors as Protective Targets in HSPCs After Irradiation.International journal of molecular sciences · 2026Article
- Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.ACS pharmacology & translational science · 2026Review
- A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.bioRxiv : the preprint server for biology · 2026Article
- [Targeting chimera technology: A new tool for undruggable in breast cancer].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma.Blood cancer journal · 2025Article
- Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma.Cell & bioscience · 2024Review
- Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.Blood cancer journal · 2024Article
- Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.Nature communications · 2024Article
- AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis.Breast cancer research : BCR · 2024Article
- Spatially Exploring RNA Biology in Archival Formalin-Fixed Paraffin-Embedded Tissues.bioRxiv : the preprint server for biology · 2024Article
- CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon.JCI insight · 2024Article
- Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.Cell death discovery · 2023Review
- Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia.Nature communications · 2023Article
- Analysis of the differential expression and prognostic relationship of DEGs in AML based on TCGA database.European journal of medical research · 2023Article
- An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.Cancer discovery · 2023Article
- TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.Molecular cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 9 institutions in 4 countries.
Neeraj JainDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3736-8621
Keenan HartertEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-5367-6640
Saber TadrosDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2887-6122
Warren FiskusDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-7343-6214
Ondrej HavranekDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5826-3557
Man Chun John MaDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2000-8144
Alyssa BouskaDepartment of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Tayla HeavicanDepartment of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Dhiraj KumarDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Qing DengDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dalia MooreEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Christine PakDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Chih Long LiuDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-6577-5427
Andrew J GentlesDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Elena HartmannInstitute of Pathology, University of Würzburg, Würzburg 97080, Germany.ORCID 0000-0003-2134-2774
Robert KridelPrincess Margaret Cancer Center, University of Toronto, Toronto, ON M5G 2C4, Canada.ORCID 0000-0003-0287-7124
Karin Ekstrom SmedbyDepartment of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm SE-171 76, Sweden.
Gunnar JuliussonDepartment of Laboratory Medicine, Stem Cell Center, Lund University, Lund SE-221 00, Sweden.
Richard RosenquistDepartment of Molecular Medicine and Surgery, Karolinska Universitetssjukhuset, Stockholm SE-171 76, Sweden.
Randy D GascoyneCenter for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
Andreas RosenwaldInstitute of Pathology, University of Würzburg, Würzburg 97080, Germany.
Filippo GiancottiDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0541-9519
Sattva S NeelapuDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jason WestinDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1824-2337
Julie M VoseDivision of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-1015-7434
Matthew A LunningDivision of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Timothy GreinerDepartment of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-1470-8328
Scott RodigDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-1761-9769
Javeed IqbalDepartment of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Ash A AlizadehDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-5153-5625
R Eric DavisDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7311-0065
Kapil BhallaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5209-5126
Michael R GreenDepartment of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. mgreen5@mdanderson.org.ORCID 0000-0001-6309-9472
The University of Texas MD Anderson Cancer Center · USUniversity of Nebraska Medical Center · USStanford University · USBrigham and Women's Hospital · USKarolinska University Hospital · SEUniversity of Würzburg · DEBC Cancer Agency · CALund University · SEPrincess Margaret Cancer Centre · CA
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0MMechanisms governing metastatic dormancy and reactivationR35CA197566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIANCOTTI, FILIPPO G · 2016 to 2022
$6.7MIdentifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP InactivationR01CA201380 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Richard Green · 2016 to 2026
$3.5MTherapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesotheliomaR01CA191222 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIANCOTTI, FILIPPO G · 2016 to 2020
$2.5MBET protein antagonist-based targeted therapy of Mantle Cell LymphomaR01CA210250 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHALLA, KAPIL · 2017 to 2021
$1.9MNCI NIH HHS P30 CA016672NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA191222NCI NIH HHS R01 CA201380NCI NIH HHS R01 CA210250NCI NIH HHS R35 CA197566
Abstract
The activated B cell (ABC-like) subtype of diffuse large B cell lymphoma (DLBCL) is characterized by chronic activation of signaling initiated by immunoglobulin μ (IgM). By analyzing the DNA copy number profiles of 1000 DLBCL tumors, we identified gains of 18q21.2 as the most frequent genetic alteration in ABC-like DLBCL. Using integrative analysis of matched gene expression profiling data, we found that the
Indexed as
AnimalsBlotting, WesternCell LineCell SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansImmunoglobulinsLymphoma, Large B-Cell, DiffuseMaleMiceMice, NudeSignal TransductionTranscription Factor 4Xenograft Model Antitumor AssaysImmunoglobulinsTCF4 protein, humanTranscription Factor 4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.